Fosaprepitant 150 mg

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC, Stanford University, Qilu Hospital of Shandong University, Montefiore Medical Center

Conditions

Anesthesia ComplicationChemotherapy-Induced Nausea and Vomiting (CINV)NauseaNausea and VomitingPostoperative NauseaPostoperative Nausea and VomitingThoracic DiseasesVomiting

Phase 1

Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

CompletedNCT01111851

Merck Sharp & Dohme LLCChemotherapy-Induced Nausea and Vomiting (CINV)

Start: 2010-04-30End: 2010-10-31Updated: 2015-02-25

Phase 2

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting

RecruitingNCT06382012

Montefiore Medical CenterNausea, Nausea and Vomiting, Vomiting

Start: 2024-11-13End: 2026-06-30Target: 250Updated: 2025-08-29

Phase 4

Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia

CompletedNCT03197064

Stanford UniversityPostoperative Nausea

Start: 2018-01-01End: 2020-01-31Updated: 2022-07-18

Unknown Phase

Antiemetic Prophylaxis With Fosaprepitant and Ondansetron in Patients Undergoing Thoracic Surgery

Qilu Hospital of Shandong UniversityAnesthesia Complication, Postoperative Nausea and Vomiting, Thoracic Diseases

Start: 2023-06-30End: 2023-06-30Target: 234Updated: 2023-06-06